- Revenue growth of 46% year-over-year to $1.0 million
- Successful expansion into Chinese market with DirectInject-LC™
- 33% team expansion to support Self-Driving Lab development
- Achievement of >99% pure battery-grade lithium carbonate production
Telescope Innovations Corp. (TELIF, Financial) has announced its financial results for the second fiscal quarter of 2025, revealing significant progress in both revenue growth and operational expansion. The company reported revenues of $1.0 million, marking a 46% increase from $686,205 in the same quarter of the previous year. Despite this growth, the adjusted EBITA loss stood at $441,837, up from a loss of $325,488 year-over-year, with expenses rising to $1.7 million from $1.3 million.
A key highlight of the quarter was the expansion of Telescope's flagship product, DirectInject-LC™, into China via a partnership with Mettler Toledo. This move capitalizes on existing commercial adoption in the US, Europe, and Japan, and positions the product for greater market penetration.
Telescope also introduced the EasyFrit sampling filter accessory to enhance process understanding in crystallization chemistry, further broadening the application scope of the DirectInject-LC™ platform.
The company's collaboration with Pfizer for the development of a Self-Driving Lab (SDL) has led to a 33% expansion in team size over the past six months. This growth is aimed at scaling SDL platforms to meet increasing demand within the pharmaceutical and chemical sectors, utilizing artificial intelligence and robotic automation for accelerated research and development.
Additionally, the successful production of battery-grade lithium carbonate with a purity of over 99% using Telescope's ReCRFT™ technology marks a significant achievement in the sustainable supply of essential battery materials.
The quarter also saw recognition for Telescope's CTO, Jason Hein, who received the 2025 R.U. Lemieux Award for his contributions to organic chemistry and process development.
